📋 Tender Overview
Malaria treatment is an urgent need that requires the development of affordable and accessible medicines for low-income regions. The Geneva-based Medicines for Malaria Venture product development partnership leads efforts for new antimalarial treatments. This work is in line with Swiss values of collaboration and innovation, contributing to equitable access to quality medicines for vulnerable groups such as children and pregnant women.
Country/region Topic Period Budget
Global
Health
nothemedefined
Malaria
Infectious desease
01.01.2025 - 31.12.2027
CHF 2’511’000
The project in brief
Background Malaria is spread by the bite of an infected Anopheles mosquito, which transmits the Plasmodium parasite into the bloodstream. Despite significant progress over the past 15 years, malaria remains a major global public health issue, with 249 million malaria cases in 2022, an increase of 5 million from 2021. Malaria is responsible for more than 600,000 deaths annually. Africa accounts for 94% of global malaria cases and 95% of deaths. In 2022, 78% of all deaths in the region were among children under five. With 25 years of successful malaria research and an innovative pipeline of antimalarial tools, Medicines for Malaria Venture (MMV) is well positioned to drive progress in towards malaria control and elimination. Medicines for Malaria Venture's strategy to 2030 focuses on developing cost-effective medicines that address malaria treatment (artemisinin) resistance, offer more convenient treatments, target vulnerable groups such as children and pregnant women, and are designed for low-cost production in partnership with malaria-endemic countries. Switzerland plays a leading role in the global fight against malaria. Swiss research institutions, pharmaceutical companies, international NGOs and international cooperation are at the forefront of this effort. SDC’s support encompasses a variety of approaches, with specific interventions in research and development, financing, and policy influencing at both global and bilateral levels. SDC's renewed support to MMV since 1999 ensures continued research and development and access to malaria prevention, vaccines, and antimalarial treatments.
Objectives Thanks to transformative antimalarial interventions, malaria in endemic countries will significantly diminish by 2030, with a focus on vulnerable population, in particular women and children.
Target groups Populations in malaria-endemic regions, particularly pregnant women and children under five. Countries at different stages of malaria elimination efforts.
Medium-term outcomes
The cure of patients while addressing resistance is improved.
The prevention of malaria by expanding modern technologies is increased.
The elimination of malaria is advanced.
Results Expected results:
Treatment resistance is delayed with an optimized use of combined drugs.
Chemoprevention to a broader population is extended.
New protective medicines for at-risk groups are
